Tardive dyskinesia (TD) can be managed, and in some cases significantly reduced, through a combination of medication changes, FDA-approved treatments, and careful monitoring. The two most effective options currently available are VMAT2 inhibitors, which are the only drugs specifically approved for TD, and switching to a different antipsychotic that carries lower risk. Most people who pursue treatment see meaningful improvement, though the degree varies based on how long TD has been present and which approach is used.
VMAT2 Inhibitors: The First-Line Treatment
Two medications are FDA-approved specifically for tardive dyskinesia: valbenazine (Ingrezza) and deutetrabenazine (Austedo). Both work by reducing the amount of dopamine packaged into nerve cells, which calms the involuntary movements characteristic of TD. In clinical trials, roughly half of patients taking these drugs experienced a meaningful reduction in symptoms within six to eight weeks.
These are typically the first medications a prescriber will consider once TD is identified. They can be taken alongside the antipsychotic or other medication that originally caused the movements, which matters because many people cannot safely stop their psychiatric medication. Side effects tend to be mild, with drowsiness being the most common complaint. Deutetrabenazine requires genetic testing beforehand because some people metabolize it differently, which affects dosing.
Switching to a Lower-Risk Antipsychotic
Not all antipsychotics carry the same TD risk. Clozapine, in particular, has strong evidence for improving TD symptoms rather than worsening them. In a retrospective study, about 72% of patients who switched to clozapine saw their involuntary movements drop by more than half, and roughly 55% had complete resolution of their dyskinesia over three years. Improvement often begins within four weeks and becomes more noticeable by one to three months.
Clozapine does require regular blood monitoring because of a rare but serious side effect involving white blood cell counts. This makes it a less convenient option, and it’s typically reserved for situations where other approaches haven’t worked or where the person’s psychiatric condition also benefits from the switch. Other second-generation antipsychotics like quetiapine also carry lower TD risk than older medications, though their ability to reverse existing TD is less well documented than clozapine’s.
Adjusting or Reducing the Causing Medication
The simplest intervention, when it’s possible, is reducing or stopping the drug that triggered TD. This is the first thing a prescriber will evaluate. The core principle is using the lowest effective dose of any dopamine-blocking medication for the shortest duration necessary. Throughout treatment, the ongoing need for these medications should be reassessed regularly, and the dose lowered when there’s room to do so.
This approach has limits. Many people take antipsychotics for conditions like schizophrenia or bipolar disorder where stopping the medication poses serious risks. Abruptly discontinuing an antipsychotic can also temporarily worsen TD symptoms before they improve, a phenomenon called withdrawal dyskinesia. Any changes to psychiatric medications need to happen gradually and with close supervision.
Regular Screening Catches TD Early
Early detection makes a real difference in outcomes. TD that’s caught within the first few months responds better to treatment than movements that have been present for years. The standard screening tool is the Abnormal Involuntary Movement Scale (AIMS), a brief physical exam where a clinician observes your face, tongue, jaw, trunk, and limbs for involuntary movements.
Current guidelines recommend AIMS screening at baseline before starting an antipsychotic, then every 12 months for most people. If you fall into a higher-risk group, screening should happen every 6 months. Higher risk applies to people over 55, those of African or African American descent, anyone with a mood disorder or intellectual disability, and people who have experienced other movement-related side effects like restlessness (akathisia) or stiffness from their medications. If you’re taking an antipsychotic and haven’t been screened recently, it’s worth asking about it.
Nutritional and Supplemental Approaches
Vitamin B6 (pyridoxine) is the most studied supplement for TD. Small studies have suggested it may help, and a formal clinical trial tested doses of 200 to 400 mg per day. However, large-scale evidence confirming its benefit is still lacking. Some clinicians recommend it as a low-risk addition to other treatments, but it shouldn’t be relied on as a primary strategy.
Vitamin E has also been investigated, with early studies suggesting it might slow TD progression rather than reverse existing symptoms. The evidence is similarly limited. Neither supplement replaces the proven options above, but they’re unlikely to cause harm at the doses studied.
Deep Brain Stimulation for Severe Cases
For people with severe tardive dyskinesia or tardive dystonia (sustained twisting postures) that hasn’t responded to medication, deep brain stimulation is an option. The procedure involves implanting small electrodes that deliver continuous electrical pulses to a movement-control region deep in the brain. In studied cases, patients experienced dramatic improvement: involuntary movements decreased by about 78% and disability scores dropped by 94% within the first week after the device was activated.
This is a surgical procedure with real risks, including infection and the need for battery replacements over time. It’s reserved for the most treatment-resistant cases where TD significantly impairs daily functioning. The results, though, can be striking for people who’ve exhausted other options.
What Tends to Work Best in Practice
Most people with TD end up using a combination of strategies. A typical path starts with evaluating whether the causing medication can be reduced, adding a VMAT2 inhibitor if movements persist, and potentially switching antipsychotics if the psychiatric condition allows it. The earlier you start treatment after TD appears, the better the chances of significant improvement.
TD that has been present for years can still improve, but it tends to respond more slowly and less completely. Consistency matters: VMAT2 inhibitors need to be taken daily to maintain their effect, and symptoms can return if they’re stopped. For many people, TD becomes a manageable condition rather than a progressive one, especially with the treatment options now available.